<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Xu Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Although CA19-9 is an essential blood biomarker of pancreatic cancer (PC), its sensitivity and specificity are limited for early detection.&lt;h4>Methods&lt;/h4>We analyzed the serum proprotein convertase subtilisin/kexin type 9 (sPCSK9) in PC patients, benign disease groups (BDG), and healthy controls (HC) by ELISA.&lt;h4>Results&lt;/h4>Consistently, sPCSK9 was considerably lower in PC patients than in HC (Z = -2.546, &lt;i>P&lt;/i> &lt; 0.05), and sPCSK9 in PC patients was statistically significantly higher than in BDG (Z = -5.457, &lt;i>P&lt;/i> &lt; 0.001). sPCSK9 was linked to the invasion of lymph nodes (χ&lt;sup>2&lt;/sup> = 6.846, &lt;i>P&lt;/i> &lt; 0.01). According to ROC curves, combining sPCSK9 with CA19-9 could potentially enhance the diagnostic capability of CA19-9 in early-stage PC patients. Furtherm</pubmed_abstract><journal>PeerJ</journal><pagination>e18018</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11397121</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.</pubmed_title><pmcid>PMC11397121</pmcid><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Xiong Q</pubmed_authors><pubmed_authors>Zhu Q</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.</name><description>&lt;h4>Background&lt;/h4>Although CA19-9 is an essential blood biomarker of pancreatic cancer (PC), its sensitivity and specificity are limited for early detection.&lt;h4>Methods&lt;/h4>We analyzed the serum proprotein convertase subtilisin/kexin type 9 (sPCSK9) in PC patients, benign disease groups (BDG), and healthy controls (HC) by ELISA.&lt;h4>Results&lt;/h4>Consistently, sPCSK9 was considerably lower in PC patients than in HC (Z = -2.546, &lt;i>P&lt;/i> &lt; 0.05), and sPCSK9 in PC patients was statistically significantly higher than in BDG (Z = -5.457, &lt;i>P&lt;/i> &lt; 0.001). sPCSK9 was linked to the invasion of lymph nodes (χ&lt;sup>2&lt;/sup> = 6.846, &lt;i>P&lt;/i> &lt; 0.01). According to ROC curves, combining sPCSK9 with CA19-9 could potentially enhance the diagnostic capability of CA19-9 in early-stage PC patients. Furtherm</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-03T20:36:51.237Z</modification><creation>2025-04-04T00:45:28.004Z</creation></dates><accession>S-EPMC11397121</accession><cross_references><pubmed>39282119</pubmed><doi>10.7717/peerj.18018</doi></cross_references></HashMap>